Rheumatoid arthritis Flashcards
What is rheumatoid arthritis
Chronic symmetrical inflammatory autoimmune disease that affects synovial joints characterised by swelling, joint pain & synovial destruction
Aetiology of rheumatoid arthritis
Genetics
Hormones (3:1 female to male ratio)
Environment (infection & smoking)
Pathophysiology of rheumatoid arthritis
Non-specific inflammation affects the synovial tissue and is amplified by T-cell activation
Auto-antibodies involved in rheumatoid arthritis
Rheumatoid factor
Anti-CCP antibodies
What is rheumatoid factor SS
Sensitivity = 50-80%
Specificity = 70-80%
- High titres are more at risk of extra-articular disease
What is Anti-CCP antibodies SS
Sensitivity = 60-70% (absence does not exclude disease as too low)
Specificity = 90- 99%
- present many years before articular symptoms (relevant to smoking current and history)
Clinical Presentations of rheumatoid arthritis
Symmetrical pain & joint swelling
Common in small joints hand & feet
Prolonged early morning stiffness
Pain improves with activity
Joint deformities
Atlanto-axial subluxation
What are the common 2 joint deformities seen in RA
Swan neck deformity = PIP hyperextension and DIP flexion
-Boutonniere deformity = PIP flexion and DIP hyperextension
What is Atlanto-axial subluxation as it occurs in RA
Misalignment of the 1st & 2nd cervical vertebrae causing excessive joint movement
Clinical Signs of RA
Swelling of affected joints
Bouchard’s nodes = on PIP joints
Positive compression tests of MCP and MTP joints
Synovial herniation - cysts e.g. Baker’s cyst
Common extra-articular manifestations
Sjogren syndrome
Raynaud’s
Malaise, weight loss, fever
Pericarditis, myocarditis
Osteoporosis
Imaging used in RA
X-ray (late disease see erosions & subluxation)
Subluxation is dislocation incomplete or partial
MRI to see disease progression
What would be seen in bloods of RA patient
high CRP, PV and ESR
RF factor or anti-CCP antibodies
Management RA 1st line
DMARDS e.g. methotrexate, sulfasalazine
(disease-modifying anti-rheumatic drugs)
aim is to start within 3 months of symptom onset
Management RA 2nd line
Biologics
Only given if 2 DMARDs have been tried and fail
e.g. Anti-TNF agents